SecBot SecBot
SECBOTREPLAY Home › Report › PASG

PASG · Merger approvals secured

Passage BIO, Inc. · 8-K filed Nov 6, 2026 at 06:05 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 6, 2026 at 06:05 ET

Passage Bio stockholders approved all proposals related to the reverse merger with Remix Therapeutics, including share issuance (representing >20% of outstanding shares and a change of control), a reverse stock split (1:2 to 1:10), name change to Remix Therapeutics, and adoption of new equity incentive and employee stock purchase plans. The merger remains subject to closing conditions, and the combined company expects to be renamed Remix Therapeutics with its lead candidate REM-422.

  • Stockholders approved issuance of Passage Bio common stock to Remix securityholders representing >20% of outstanding shares and resulting in a change of control (Proposal 1: 1,806,227 for, 36,404 against).
  • Stockholders approved a reverse stock split at a ratio from 1-for-2 to 1-for-10, with the final ratio to be mutually agreed by Passage Bio and Remix (Proposal 2: 2,202,453 for, 113,608 against).
  • Stockholders approved amending the charter to change the company name to Remix Therapeutics, Inc. (Proposal 3: 1,809,243 for, 33,290 against).
  • Stockholders approved the Remix Therapeutics 2026 Equity Incentive Plan, reserving 5,772,500 shares (pre-split) plus annual increases (Proposal 5: 1,383,770 for, 458,604 against).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access